Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | Thymidine kinase | 0.0259 | 1 | 0.5 |
Echinococcus granulosus | thymidylate synthase | 0.0111 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable thymidylate synthase ThyA (ts) (TSASE) | 0.0111 | 0 | 0.5 |
Loa Loa (eye worm) | thymidylate synthase | 0.0111 | 0 | 0.5 |
Schistosoma mansoni | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0111 | 0 | 0.5 |
Trichomonas vaginalis | thymidine kinase, putative | 0.0259 | 1 | 0.5 |
Leishmania major | thymidine kinase, putative | 0.0259 | 1 | 1 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.0157 | 0.3083 | 0.5 |
Brugia malayi | thymidylate synthase | 0.0111 | 0 | 0.5 |
Trypanosoma cruzi | thymidine kinase, putative | 0.0259 | 1 | 1 |
Mycobacterium leprae | PROBABLE THYMIDYLATE SYNTHASE THYA (TS) (TSASE) | 0.0111 | 0 | 0.5 |
Mycobacterium ulcerans | thymidylate synthase | 0.0111 | 0 | 0.5 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0157 | 0.3083 | 0.5 |
Onchocerca volvulus | 0.0111 | 0 | 0.5 | |
Trichomonas vaginalis | thymidine kinase, putative | 0.0259 | 1 | 0.5 |
Echinococcus multilocularis | thymidylate synthase | 0.0111 | 0 | 0.5 |
Trypanosoma brucei | thymidine kinase | 0.0259 | 1 | 1 |
Trichomonas vaginalis | thymidine kinase, putative | 0.0259 | 1 | 0.5 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0157 | 0.3083 | 0.5 |
Trypanosoma cruzi | thymidine kinase, putative | 0.0259 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | > 300 uM | Displacement of [3H]epibatidine from rat alpha4beta2 nAChR transfected in HEK293 cells after 4 hrs by scintillation count analysis | ChEMBL. | 25050162 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.